Cite

HARVARD Citation

    Harada, D. et al. (2021). Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial. Thoracic cancer. 12 (5), pp. 643-649. [Online]. 
  
Back to record